2006
DOI: 10.1016/j.bmc.2005.08.041
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis and in vitro anti-hepatitis B virus activities of some ethyl 6-bromo-5-hydroxy-1H-indole-3-carboxylates

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
68
0
1

Year Published

2008
2008
2016
2016

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 100 publications
(70 citation statements)
references
References 10 publications
1
68
0
1
Order By: Relevance
“…They separated the center of mass movement of ligand from its internal and rotational motions. (Friedman and Caflisch, 2009), target for malaria Flavivirus Proteases (Ekonomiuk et al, 2009a,b), target for WNV and Dengue virus Tyrosine kinase erythropoietin-producing human hepatocellular carcinoma receptor B4 (EphB4) (Lafleur et al, 2009) FlexX Plasmepsin II and IV inhibitors (Luksch et al, 2008), malaria Anthrax edema factor Pneumococcal peptidoglycan deacetylase inhibitors (Bui et al, 2011) Glide Aurora kinases inhibitors (Warner et al, 2006) Falcipain inhibitors (Shah et al, 2011) Cytochrome P450 inhibitors (Caporuscioi et al, 2011) Surflex Topoisomerase I, anticancer (optimization) DOCK FK506 immunophilin (Zhao et al, 2006) BCL6, oncogene in B-cell lymphomas (Cerchietti et al, 2010) 348…”
Section: Sampling Algorithms For Protein-ligand Dockingmentioning
confidence: 99%
See 2 more Smart Citations
“…They separated the center of mass movement of ligand from its internal and rotational motions. (Friedman and Caflisch, 2009), target for malaria Flavivirus Proteases (Ekonomiuk et al, 2009a,b), target for WNV and Dengue virus Tyrosine kinase erythropoietin-producing human hepatocellular carcinoma receptor B4 (EphB4) (Lafleur et al, 2009) FlexX Plasmepsin II and IV inhibitors (Luksch et al, 2008), malaria Anthrax edema factor Pneumococcal peptidoglycan deacetylase inhibitors (Bui et al, 2011) Glide Aurora kinases inhibitors (Warner et al, 2006) Falcipain inhibitors (Shah et al, 2011) Cytochrome P450 inhibitors (Caporuscioi et al, 2011) Surflex Topoisomerase I, anticancer (optimization) DOCK FK506 immunophilin (Zhao et al, 2006) BCL6, oncogene in B-cell lymphomas (Cerchietti et al, 2010) 348…”
Section: Sampling Algorithms For Protein-ligand Dockingmentioning
confidence: 99%
“…SB-vHTS has been used successfully in identifying novel and potent hits in several drug discovery campaigns Lu et al, 2006;Zhao et al, 2006;Ruiz et al, 2008;Triballeau et al, 2008;Li et al, 2009;Budzik et al, 2010;Izuhara et al, 2010;Simmons et al, 2010;Roughley et al, 2012). We discuss two examples in which SB-vHTS played pivotal role in discovery of lead compounds.…”
Section: E Structure-based Virtual High-throughput Screeningmentioning
confidence: 99%
See 1 more Smart Citation
“…It is less likely to induce drug resistance than other compounds, such as adamantine and oseltamivir [11,12,16,18] . However, its mechanism is complicated: earlier reports indicated that ARB could inhibit the membrane fusion of enveloped viruses in vitro and strengthen the interactions between virus glycoprotein and the membrane of host during the endocytosis [17,19,20] .…”
Section: Introductionmentioning
confidence: 99%
“…Today, analogues based on indole are significant players in a diverse array of markets such as dyes, plastics, agriculture, vitamin supplements, over-thecounter drugs, flavour enhancers and perfumery (Barden, 2011). Indole derivatives exhibit antibacterial, antifungal (Singh et al 2000), antitumor (Andreani et al, 2001), antihepatitis B virus (Chai et al, 2006) and anti-inflammatory (Rodriguez et al, 1985) activities. They are also used as bioactive drugs (Stevenson et al, 2000) and exhibit high aldose reductase inhibitory (Rajeswaran et al, 1999) and antimicrobial activities (Amal Raj et al, 2003).…”
Section: Structure Descriptionmentioning
confidence: 99%